Document is current
Any future updates will be listed below
-
Authors
van Lemmen, Maarten A. https://orcid.org/0000-0001-8767-1824
van Velzen, Monique https://orcid.org/0000-0002-0289-6432
Sarton, Elise Y.
Dahan, Albert https://orcid.org/0000-0003-3161-3945
Niesters, Marieke
van der Schrier, Rutger M. https://orcid.org/0000-0003-1422-3830
-
Funding
Funding for this research was provided by:
DMK and ZMI Pharma donated the intramuscular naloxone used in this study.
- License Information
-
More Information
Article History
Received: 10 September 2024
Accepted: 9 May 2025
First Online: 19 May 2025
Competing interests
: A.D. received sponsor/consultancy/speaker fees from Enalare Therapeutics, Inc. (USA), Zmi Pharma, Inc. (USA), Takeda Pharmaceuticals Inter. A.G. (Switzerland). and Trevena, Inc. (USA), and an award from the US Food & Drug Administration (USA). The other authors report no conflict of interest. The study was sponsored by departmental funds. Intramuscular naloxone (ZIMHI) was kindly donated by DMK Pharmaceuticals Co., San Diego, CA, USA, and Zmi Pharma Inc, Carlsbad, CA, USA. These donors had no role in the study design, data collection, data analysis or manuscript writing.
